These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20852151)

  • 1. Medicare bundles medications into ESRD payments.
    Thompson CA
    Am J Health Syst Pharm; 2010 Oct; 67(19):1580-4. PubMed ID: 20852151
    [No Abstract]   [Full Text] [Related]  

  • 2. Medicare ESRD prospective payment system: weighing the evidence.
    Himmelfarb J; Chertow GM
    J Am Soc Nephrol; 2005 May; 16(5):1164-5. PubMed ID: 15829705
    [No Abstract]   [Full Text] [Related]  

  • 3. Medicare program; end-stage renal disease prospective payment system. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2010 Aug; 75(155):49029-214. PubMed ID: 20712086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, and End-Stage Renal Disease Quality Incentive Program. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2017 Nov; 82(210):50738-97. PubMed ID: 29091373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicare programs: changes to the end-stage renal disease prospective payment system transition budget-neutrality adjustment. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2011 Apr; 76(66):18930-4. PubMed ID: 21491804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using race as a case-mix adjustment factor in a renal dialysis payment system: potential and pitfalls.
    Roach JL; Turenne MN; Hirth RA; Wheeler JR; Sleeman KS; Messana JM
    Am J Kidney Dis; 2010 Nov; 56(5):928-36. PubMed ID: 20888100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Financial implications to Medicare from changing the dialysis modality mix under the bundled prospective payment system.
    Liu FX; Walton SM; Leipold R; Isbell D; Golper TA
    Perit Dial Int; 2014; 34(7):749-57. PubMed ID: 25292402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cost of Transferring Dialysis Care From the Employer-Based Market to Medicare.
    Lin E
    JAMA Netw Open; 2021 Mar; 4(3):e212113. PubMed ID: 33734412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dialysis bundling and small dialysis organizations: a call for close monitoring.
    Slinin Y; Ishani A
    Am J Kidney Dis; 2013 Jun; 61(6):858-60. PubMed ID: 23684490
    [No Abstract]   [Full Text] [Related]  

  • 10. Medicare program; end-stage renal disease prospective payment system, quality incentive program, and bad debt reductions for all Medicare providers. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2012 Nov; 77(218):67450-531. PubMed ID: 23139948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 2011 ESRD prospective payment system: welcome to the bundle.
    Weiner DE
    Am J Kidney Dis; 2011 Apr; 57(4):539-41. PubMed ID: 21333431
    [No Abstract]   [Full Text] [Related]  

  • 12. Managing oral phosphate binder medication expenditures within the Medicare bundled end-stage renal disease prospective payment system: economic implications for large U.S. dialysis organizations.
    Park H; Rascati KL; Keith MS
    J Manag Care Spec Pharm; 2015 Jun; 21(6):507-14. PubMed ID: 26011552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 2011 ESRD prospective payment system: an uncontrolled experiment.
    Winkelmayer WC; Chertow GM
    Am J Kidney Dis; 2011 Apr; 57(4):542-6. PubMed ID: 21333428
    [No Abstract]   [Full Text] [Related]  

  • 14. The 2011 ESRD prospective payment system: perspectives from a for-profit small- to medium-sized dialysis organization.
    Bhat P; Bhat JG
    Am J Kidney Dis; 2011 Apr; 57(4):556-8. PubMed ID: 21316132
    [No Abstract]   [Full Text] [Related]  

  • 15. The 2011 ESRD prospective payment system: perspectives from Fresenius Medical Care, a large dialysis organization.
    Lacson E; Hakim RM
    Am J Kidney Dis; 2011 Apr; 57(4):547-9. PubMed ID: 21333423
    [No Abstract]   [Full Text] [Related]  

  • 16. The 2011 ESRD prospective payment system: perspectives from DaVita, a for-profit large dialysis organization.
    Nissenson AR; Mayne TJ; Krishnan M
    Am J Kidney Dis; 2011 Apr; 57(4):550-2. PubMed ID: 21333425
    [No Abstract]   [Full Text] [Related]  

  • 17. The 2011 ESRD prospective payment system and the survival of an endangered species: the perspective of a not-for-profit medium-sized dialysis organization.
    Johnson DS; Meyer KB; Johnson HK
    Am J Kidney Dis; 2011 Apr; 57(4):553-5. PubMed ID: 21333427
    [No Abstract]   [Full Text] [Related]  

  • 18. Medicare Program; End-Stage Renal Disease Prospective Payment System, and Quality Incentive Program. Final Rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2015 Nov; 80(215):68967-9077. PubMed ID: 26552112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The due diligence on the ESRD payment cut.
    Neumann ME
    Nephrol News Issues; 2013 Oct; 27(11):8. PubMed ID: 24288801
    [No Abstract]   [Full Text] [Related]  

  • 20. Association of Medicare's Bundled Payment Reform With Changes in Use of Vitamin D Among Patients Receiving Maintenance Hemodialysis: An Interrupted Time-Series Analysis.
    Spoendlin J; Schneeweiss S; Tsacogianis T; Paik JM; Fischer MA; Kim SC; Desai RJ
    Am J Kidney Dis; 2018 Aug; 72(2):178-187. PubMed ID: 29891194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.